BlackRock Inc. Purchases Shares of 24,592,166 Becton, Dickinson and Company $BDX

Key Points

• BlackRock acquired 24.6 million Becton, Dickinson and Company shares worth approximately $3.72 billion, giving it an 8.93% stake. Institutional investors collectively own 86.97% of BDX.
• Analyst sentiment is mixed, with eight Buy, eight Hold and one Sell rating; the consensus rating is Hold and the average price target is $185.67.
• BDX beat quarterly earnings and revenue estimates, reporting $3.23 in EPS and $4.98 billion in revenue, while maintaining fiscal 2026 EPS guidance of $12.62–$12.72. The company also declared a quarterly dividend of $1.05 per share, yielding about 2.3% annually.

BlackRock Inc. acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,592,166 shares of the medical instruments supplier's stock, valued at approximately $3,721,533,000. BlackRock Inc. owned about 8.93% of Becton, Dickinson and Company at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $25,000. SHP Wealth Management bought a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $26,000. Meeder Asset Management Inc. lifted its stake in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 102 shares during the period. Main Street Group LTD purchased a new stake in Becton, Dickinson and Company in the first quarter worth $29,000. Finally, Bell Investment Advisors Inc bought a new stake in Becton, Dickinson and Company in the second quarter valued at $29,000. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on BDX shares. Barclays upped their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a report on Monday, May 11th. Bank of America reduced their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. TD Cowen increased their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a "hold" rating in a research note on Wednesday, August 5th. Wells Fargo & Company raised their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. Finally, The Goldman Sachs Group reduced their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of "Hold" and an average price target of $185.67.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the company's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares of the company's stock, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 11,779 shares of company stock worth $1,974,669. Company insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Trading Down 0.5%

NYSE:BDX opened at $181.17 on Wednesday. The stock has a market cap of $49.92 billion, a price-to-earnings ratio of 54.57, a PEG ratio of 12.93 and a beta of 0.19. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company's 50 day moving average price is $159.06 and its 200-day moving average price is $161.12. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company's revenue was up 5.4% compared to the same quarter last year. During the same period last year, the business posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company's payout ratio is 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source